Your genes may determine if diabetes drug works
NCT ID NCT06256419
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at how a person's genes influence their response to GLP-1 RA drugs (like exenatide and liraglutide) for type 2 diabetes. Researchers will analyze blood samples from 300 patients to find genetic markers that predict whether the drug lowers blood sugar and weight. The goal is to personalize diabetes treatment based on genetics.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GLP-1 receptor agonists (exenatide, liraglutide)
What this could lead to
If successful, this could help doctors predict which type 2 diabetes patients will benefit most from GLP-1 RA drugs, leading to more personalized treatment.
What could go wrong
This is a retrospective study, not a controlled trial, so it can show links but not prove cause and effect. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China, Jiangsu, Department of Endocrinology
RECRUITINGXuzhou, China, 221006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact